Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability

Journal of Surgical Oncology

Volumn 111, Issue 8, 2015, Pages 1028-1034

  Nanda, Ronica H ^a   El Rayes, Bassel ^b   Maithel, Shishir K ^b   Landry, Jerome ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

FOLFIRINOX; neoadjuvant therapy; pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CAPECITABINE; DEOXYCYTIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; PLATINUM COMPLEX;

ADENOCARCINOMA; ADJUVANT THERAPY; ADULT; AGED; ANALOGS AND DERIVATIVES; CHEMORADIOTHERAPY; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMORADIOTHERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84934301146     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23921     Document Type: Article

References (18)

1. Brennan MF, Moccia RD, Klimstra D,: Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg 1996; 223: 506-511.
2. Huguet F, Andre T, Hammel P, et al.,: Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25: 326-331.
3. Leone F, Gatti M, Massucco P, et al.,: Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer. Cancer 2013; 119: 277-284.
4. Conroy T, Desseigne F, Ychou M, et al.,: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
5. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al.,: Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013; 31: 23-29.
6. Marthey L, Sa-Cunha A, Blanc JF, et al.,: FOLFIRINOX for locally advanced pancreatic adenocarcinoma: Results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol 2014; 22: 295-301.
7. Blazer M, Wu C, Goldberg RM, et al.,: Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas. Ann Surg Oncol 2014; 22: 1153-1159.
8. Mahaseth H, Brutcher E, Kauh J, et al.,: Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas 2013; 42: 1311-1315.
9. Marubini, E., Valsecchi, M.G.,: 1995. Analyzing Survival Data from Clinical Trials and Observational Studies. John Wiley & Sons, New York.
10. Cox DR, Regression models and life tables. J Royal Stat Society 1972; B34: 187-220.
11. Burris HA, Morre MJ, Andersen J, et al.,: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413.
12. Krishnan S, Rana V, Janjan NA, et al.,: Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007; 110: 47-55.
13. Hosein PJ, Macintyre J, Kawamura C, et al.,: A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 2012; 12: 199.
14. Strobel O, Berens V, Hinz Ulf, et al.,: Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer. Surgery 2012; 152: S33-S42.
15. Chauffert B, Mornex F, Bonnetain F, et al.,: Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study [Abstract]. J Clin Oncol 2006; 24 (Suppl 18):A-4008, 180s.
16. Loehrer PJ, Sr, Feng Y, Cardenes H, et al.,: Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial. J Clin Oncol 2011; 29: 4105-4112.
17. Mukherjee S, Hurt CN, Bridgewater J, et al.,: Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial. Lancet Oncol 2013; 14: 317-326.
18. La Torre M, Ziparo V, Nigri G, et al.,: Malnutrition and pancreatic surgery: Prevalence and outcomes. J Surg Oncol 2013; 107: 702-708.